

# A Brief Note on Adult experiences with Myasthenia Gravis

Department of Pharmacology, Federal University of São Paulo, Brazil

## Introduction

Myasthenia Gravis (MG) is a chronic autoimmune disease characterized by fluctuating muscle weakness and fatigue. It is caused by autoantibodies that block, alter or destroy acetylcholine receptors (AChR) at the neuromuscular junction (NMJ). The clinical presentation is highly variable, ranging from mild ocular symptoms to severe respiratory and bulbar involvement. The diagnosis is based on clinical history, physical examination, and specific laboratory tests, including serological detection of AChR antibodies and electrophysiological studies such as repetitive nerve stimulation (RNS) and single-fiber electromyography (SFEMG). Treatment options include acetylcholinesterase inhibitors (AChEIs) and immunosuppressive therapies. Despite advances in treatment, MG remains a challenging condition due to its chronic nature and potential for relapse. This brief note discusses the adult experiences with MG, focusing on the impact of the disease on daily life, the challenges of diagnosis and treatment, and the importance of patient education and support.

---

(2003) Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. *Brain* 126: 1409-1418.

3. Arawaka S, Daimon M, Sasaki H, Suzuki JI, Kato T (1998) A novel autoantibody in paraneoplastic sensory-dominant neuropathy reacts with brain-type creatine kinase. *Int J Mol* 1:597-600.

4. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, et al.

(2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes.